Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies

Autor: Thiago Vidotto, Isaac Bai, Jeffrey J. Tosoian, Dongyao Yan, Daniela C. Salles, Shalini Singh, Andrea Muranyi, Tamara L. Lotan, Farzana A. Faisal, Liana B. Guedes, Kandavel Shanmugam
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Adult
Male
medicine.medical_specialty
medicine.medical_treatment
Chromogenic in situ hybridization
Kaplan-Meier Estimate
Pathology and Forensic Medicine
Proto-Oncogene Proteins c-myc
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Prostate
Internal medicine
Biopsy
Carcinoma
medicine
Biomarkers
Tumor
PTEN
Humans
Aged
Neoplasm Staging
biology
medicine.diagnostic_test
Prostatectomy
business.industry
PTEN Phosphohydrolase
Prostatic Neoplasms
Reproducibility of Results
Regular Article
Odds ratio
Middle Aged
medicine.disease
Prognosis
Immunohistochemistry
030104 developmental biology
medicine.anatomical_structure
Molecular Diagnostic Techniques
030220 oncology & carcinogenesis
biology.protein
Molecular Medicine
Neoplasm Grading
business
Protein Binding
Zdroj: The Journal of Molecular Diagnostics : JMD
ISSN: 1943-7811
1525-1578
Popis: This study leveraged a gene-protein assay to assess MYC and PTEN status at prostate cancer biopsy and examined the association with adverse outcomes after surgery. MYC gain and PTEN loss were simultaneously assessed by chromogenic in situ hybridization and immunohistochemistry, respectively, using 277 Grade Group 2 needle biopsies that were followed by prostatectomy. The maximal size of cribriform Gleason pattern 4 carcinoma (CRIB), the presence of intraductal carcinoma (IDC), and percentage of Gleason pattern 4 carcinoma at biopsy were also annotated. MYC gain or PTEN loss was present in 19% and 18% of biopsies, respectively, whereas both alterations were present in 9% of biopsies. Tumors with one or both alterations were significantly more likely to have non–organ-confined disease (NOCD) at radical prostatectomy. In logistic regression models, including clinical stage, tumor volume on biopsy, and presence of CRIB/IDC, cases with MYC gain and PTEN loss remained at higher risk for NOCD (odds ratio, 6.23; 95% CI, 1.74–24.55; P = 0.005). The area under the curve for a baseline model using CAPRA variables (age, prostate-specific antigen, percentage of core involvement, clinical stage) was increased from 0.68 to 0.69 with inclusion of CRIB/IDC status and to 0.75 with MYC/PTEN status. Dual MYC/PTEN status can be assessed in a single slide and is independently associated with increased risk of NOCD for Grade Group 2 biopsies.
Databáze: OpenAIRE
Externí odkaz: